16. CARDIOVASCULAR RISK STRATIFICATION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT OUTPATIENT CLINICS, NHAN DAN GIA DINH HOSPITAL

Nguyen Thi Thu Thuy1, Dinh Quoc Bao1, Nguyen Van Si1
1 University of Medicine and Pharmacy at HCMC

Main Article Content

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a popular condition and cardiovascular risk factor in Vietnam. Thanks to advanced diagnostic and treatment methods, individuals with T2DM have an extended life expectancy. However, this comes with increased diabetes-related complications, including cardiovascular diseases. Understanding cardiovascular risk and cardiovascular disease characteristics is essential in effectively caring for individuals with T2DM.


Aims: The study was conducted to estimate the global cardiovascular risk and cardiovascular disease in T2DM patients at outpatient clinics.


Method: A descriptive cross-sectional study was conducted at the endocrinology clinic and cardiology clinic of Nhan Dan Gia Dinh Hospital from March 2021 to March 2022. The hospital’s Ethics Committee approved the study with protocol number 37/NDGĐ-HĐĐĐ dated 30/3/2022


Results: A total of 515 patients participated in the study, with an average age of 66, higher in the cardiology clinic than the endocrinology clinic. Female gender dominance was observed in both clinics. Cardiovascular risk ranged from high to very high and differed between the two clinics, with high risk being predominant in the endocrinology clinic and very high risk being predominant in the cardiology clinic. Cardiovascular diseases included Coronary artery disease at 47.8%, stroke at 2.5%, heart failure at 4.9%, and peripheral artery disease at 0.6%.


Conclusion: T2DM patients receiving outpatient treatment at Nhan Dan Gia Dinh Hospital have a cardiovascular risk ranging from high to very high, with a notable prevalence of cardiovascular disease, even in the endocrinology clinic. Therefore, comprehensive control of cardiovascular risk factors and appropriate selection of blood glucose-lowering treatments for this high-risk group are crucial.

Article Details

References

[1] The World Bank, Diabetes prevalence (% of
population ages 20 to 79) – Vietnam. https://
data.worldbank.org/indicator/SH.STA.DIAB.
ZS?locations=VN
[2] Ke C, Lipscombe LL, Weisman A et al.,
Trends in the Association Between Diabetes
and Cardiovascular Events, 1994-2019. JAMA.
2022 Nov 8;328(18):1866-1869. doi: 10.1001/
jama.2022.14914. PMID: 36239969; PMCID:
PMC9568883.
[3] Balakumar P, Maung-U K, Jagadeesh G,
Prevalence and prevention of cardiovascular
disease and diabetes mellitus. Pharmacol Res.
2016 Nov;113(Pt A):600-609. doi: 10.1016/j.
phrs.2016.09.040. Epub 2016 Sep 30. PMID:
27697647.
[4] Shaughnessy AF, ADA/EASD Updated
Guidelines: Glycemic Control Is Only Part of
the Management of Type 2 Diabetes. Am Fam
Physician. 2023 May;107(5):Online. PMID:
37192089.
[5] Davies MJ, Aroda VR, Collins BS et al.,
Management of Hyperglycemia in Type 2
Diabetes, 2022. A Consensus Report by the
American Diabetes Association (ADA) and
the European Association for the Study of
Diabetes (EASD). Diabetes Care. 2022 Nov
1;45(11):2753-2786. doi: 10.2337/dci22-0034.
PMID: 36148880; PMCID: PMC10008140.
[6] Regassa LD, Tola A, Ayele Y, Prevalence of
Cardiovascular Disease and Associated Factors
Among Type 2 Diabetes Patients in Selected
Hospitals of Harari Region, Eastern Ethiopia.
Front Public Health. 2021 Feb 5;8:532719. doi:
10.3389/fpubh.2020.532719. PMID: 33614562;
PMCID: PMC7892600.
[7] Bộ Y tế, Hướng dẫn chẩn đoán và điều trị đái
tháo đường típ 2 (Ban hành kèm theo Quyết định
số 5481/QĐ-BYT ngày 30 tháng 12 năm 2020).
https://daithaoduong.kcb.vn/huong-dan-chan
doan-va-dieu-tri-dai-thao-duong-tip-2
[8] Cosentino F, Grant PJ, Aboyans V et al., ESC
Scientific Document Group. 2019 ESC Guidelines
on diabetes, pre-diabetes, and cardiovascular130
diseases developed in collaboration with the
EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.
doi: 10.1093/eurheartj/ehz486. Erratum in:
Eur Heart J. 2020 Dec 1;41(45):4317. PMID:
31497854.
[9] Nguyễn Văn Tuấn, Phan Thị Hà Linh, Rối loạn
lipid máu và nguy cơ tim mạch ở bệnh nhân đái
tháo đường type 2; Tạp chí Y học Việt Nam,
513(1), 2022, https://doi.org/10.51298/vmj.
v513i1.2353
[10] Soetedjo NNM, McAllister SM, UgarteGil C et al.,
TANDEM Consortium. Disease
characteristics and treatment of patients
with diabetes mellitus attending government
health services in Indonesia, Peru, Romania
and South Africa. Trop Med Int Health. 2018
Oct;23(10):1118-1128. doi: 10.1111/tmi.13137.
Epub 2018 Sep 10. PMID: 30106222.
[11] Kalra S, Sharma SK, Diabetes in the Elderly.
Diabetes Ther. 2018 Apr;9(2):493-500. doi:
10.1007/s13300-018-0380-x. Epub 2018 Feb 19.
PMID: 29460258; PMCID: PMC6104259.
[12] Kubota Y, Shimizu W, Clinical Benefits of
Sodium-Glucose Cotransporter 2 Inhibitors and
the Mechanisms Underlying Their Cardiovascular
Effects. JACC Asia; 2022 Jun 7;2(3):287-
293. doi: 10.1016/j.jacasi.2022.03.009. PMID:
36338417; PMCID: PMC9627935.
[13] Ussher JR, Drucker DJ, Glucagon-like peptide
1 receptor agonists: cardiovascular benefits and
mechanisms of action. Nat Rev Cardiol. 2023
Jul;20(7):463-474. doi: 10.1038/s41569-023-
00849-3, Epub 2023 Mar 28. PMID: 36977782.